Thursday, October 15, 2026

Waddell & Reed Financial, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Waddell & Reed Financial, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Waddell & Reed Financial, Inc.

21.2% sales growth and 9.34% return on equity

Waddell & Reed Financial, Inc., through its subsidiaries, provides investment management and advisory, investment product underwriting and distribution, and shareholder services administration to mutual funds, and institutional and separately managed accounts in the United States.

Waddell & Reed Financial, Inc.'s sales growth this year is anticipated to be 7.7% and a negative 0.8% for next year.

Year-on-year quarterly revenue growth grew by 3%, now sitting on 1.05B for the twelve trailing months.

Waddell & Reed Financial, Inc.'s sales growth for the next quarter is 21.2%. The company's growth estimates for the current quarter and the next is 50% and 28.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.34%.

Waddell & Reed Financial, Inc.'s Stock Yearly Top and Bottom Value

Waddell & Reed Financial, Inc.'s stock is valued at $24.95 at 23:22 EST, under its 52-week high of $25.90 and way higher than its 52-week low of $11.87.

Waddell & Reed Financial, Inc.'s Moving Average

Waddell & Reed Financial, Inc.'s value is under its 50-day moving average of $25.08 and way higher than its 200-day moving average of $22.05.

3. Omnicell, Inc.

32% sales growth and 3.55% return on equity

Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally.

Omnicell, Inc.'s sales growth this year is expected to be 22.4% and 11.9% for next year.

Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 892.21M for the twelve trailing months.

Omnicell, Inc.'s sales growth is a negative 0% for the ongoing quarter and 32% for the next. The company's growth estimates for the current quarter and the next is a negative 0% and 127%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.55%.

Volatility

Omnicell, Inc.'s last day, last week, and last month's current volatility was 2.34%, 1.07%, and 1.53%, respectively.

Omnicell, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.01% (day), 2.38% (last week), and 3.47% (last month), respectively.

Omnicell, Inc.'s Stock Yearly Top and Bottom Value

Omnicell, Inc.'s stock is valued at $137.52 at 23:22 EST, under its 52-week high of $146.00 and way above its 52-week low of $56.16.

Omnicell, Inc.'s Moving Average

Omnicell, Inc.'s value is higher than its 50-day moving average of $132.43 and way above its 200-day moving average of $110.28.

4. Badger Meter, Inc.

25.6% sales growth and 14.25% return on equity

Badger Meter, Inc. manufactures and markets flow measurement, control, and communication solutions in the United States, Asia, Canada, Europe, Mexico, the Middle East, and internationally.

Badger Meter, Inc.'s sales growth this year is expected to be 13.9% and 4.8% for next year.

Year-on-year quarterly revenue growth grew by 4.4%, now sitting on 425.54M for the twelve trailing months.

Badger Meter, Inc.'s sales growth for the next quarter is 25.6%. The company's growth estimates for the present quarter and the next is 2.4% and 24.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.25%.

Volatility

Badger Meter, Inc.'s last day, last week, and last month's current volatility was 0.03%, 0.48%, and 1.42%, respectively.

Badger Meter, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.54% (day), 1.79% (last week), and 2.74% (last month), respectively.

Badger Meter, Inc.'s Stock Yearly Top and Bottom Value

Badger Meter, Inc.'s stock is valued at $95.85 at 23:22 EST, way under its 52-week high of $111.77 and way above its 52-week low of $52.09.

Badger Meter, Inc.'s Moving Average

Badger Meter, Inc.'s value is below its 50-day moving average of $100.80 and higher than its 200-day moving average of $88.38.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com